Director Michael Thomas Henderson sells 80,000 shares for ~$5.95M as stock rallies sharply from 52-week lows.
Michael Thomas Henderson, a director at Spyre Therapeutics, disposed of a substantial portion of his holdings—80,000 shares totaling nearly $6M—in four tranches on the same day. This marks a significant shift in his insider activity: his prior Form 4 filings show 20 consecutive sales and no open-market purchases over the look-back period. The timing is notable given the stock's dramatic price trajectory—it has surged over 40% in the past month alone and more than doubled over three months from deeply depressed levels near its 52-week low. However, Henderson's selling pattern carries mixed track record implications: while his prior sales have shown a 35% win rate of being well-timed (where a 90-day decline would validate the sale), his overall 90-day returns after selling have been modestly positive, suggesting the stock often continued rising after his exits. Spyre remains unprofitable with no revenue, positioning any insider activity in a pre-commercial biotech context where cash management and equity decisions carry operational weight.
CEO Turtle Cameron sells over $1M in SYRE stock across six tranches on same day
Turtle Cameron, Spyre's Chief Executive Officer, executed a coordinated liquidation of over $1M in company stock across six separate trades in a single trading session, reducing his holdings by roughly three percent. The transactions span a narrow price range and occur against a backdrop of fundamental deterioration — the company is burning cash at a significant rate with no revenue generation, making this CEO sell particularly notable as a potential signal that leadership sees limited near-term catalysts to drive upside. The methodical, high-volume nature of the sale (multiple tranches rather than one lump transaction) suggests a deliberate exit strategy rather than a routine rebalancing. For a pre-revenue biotech burning substantial quarterly losses, a sitting CEO liquidating this scale of personal holdings during a single session warrants scrutiny into whether management retains confidence in the company's value proposition or capital runway.
Add SYRE to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.
